2011: Future Investment
The One North East Capital Grant has also been awarded to CRB in order to invest for the year 2011. With this grant CRB not only wants to expand in staff and premises but also wants to offer new and improved services.
The new capital will allow CRB to expand its capacity to synthesise long and complex peptides through the purchase of a Liberty Peptide Synthesiser, one of the most advanced instruments of its kind and a new flatbed synthesiser to double capacity. The new synthesiser’s microwave technology will enable CRB to make more difficult and higher purity peptides up to 10 times faster than by conventional methods.
Our peptide customers in the pharmaceutical drug discovery sector and in academic disease research will benefit from our ability to produce increasingly complex peptides, as well as more exotic ones. Our antibody customers will find that we can now make highly specific antibodies from both long and challenging peptides.
“In our work, the microwave capacity of the Liberty speeds up coupling reactions and recently allowed us to synthesise PNA of up to 23 residues in yields much higher than we could obtain previously with a more conventional peptide synthesizer. This has particularly aided our research on developing in vivo targeting of microRNAs by PNA.” Mike Gait Medical Research Council, Laboratory of Molecular Biology, Cambridge, UK |
